AlloMap Molecular Expression Test: Clinical trial started

CareDx (formerly XDx) started the Donor-derived cell-free DNA Outcomes AlloMap Registry (D-OAR) to examine the utility of donor-derived cell-free DNA (dd-cfDNA) in a heart transplant recipient’s blood as a surveillance tool to monitor and diagnose rejection. According to the company, dd-cfDNA is a potential biomarker for cellular injury caused by rejection. CareDx said the biomarker and its AlloMap Molecular Expression Test measure different signals of rejection in the blood and could be additive approaches. ...